Oxford vaccine, looking very good

US Influenza Oxford / AstraZeneca Phase 2 / 3 https://www.thelancet.com/journals/la... (23rd November) https://www.astrazeneca.com/media-cen... Viral vector, weakened version, chimpanzee, common cold adenovirus After vaccination, the surface spike protein is produced Antibodies T cells Interim report, 131 confirmed infections Positive high-level results 8,000 swabs per week Therefore picking up asymptomatics Clinical trials of AZD1222 UK and Brazil data only Vaccine was highly effective in preventing COVID-19 No hospitalisations or severe cases of the disease were reported in participants receiving the vaccine Group one, n = 2,741 AZD1222 was given as a half dose Followed by a full dose At least one month apart Vaccine efficacy of 90% Group 2, n = 8,895 Two full doses at least one month apart Vaccine efficacy 62 % Combined analysis from both dosing regimens, n = 11,636 An average efficacy of 70% All results were statistically significant (p less than = 0.0001) One in 10,000 More data will continue to accumulate Refining the efficacy reading Establishing the duration of protection. Independent Data Safety Monitoring Board Met its primary endpoint Protection from COVID-19 occurring 14 days or more after receiving two doses No serious safety events related to the vaccine have been confirmed AZD1222 was well tolerated across both dosing regimens AstraZeneca immediately prepare regulatory submission Early approval Emergency Use Listing from the World Health Organization For an accelerated pathway to low-income countries Full analysis of the interim results is being submitted for peer-reviewed journal Professor Andrew Pollard These findings show that we have an effective vaccine that will save many lives Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply Pascal Soriot, Chief Executive Officer Simple supply chain no-profit pledge commitment to broad, equitable and timely access means it will be affordable and globally available supplying hundreds of millions of doses on approval Control group Meningococcal conjugate vaccine called MenACWY or saline Participants Aged 18 years or over Diverse racial and geographic groups Healthy or have stable underlying medical conditions Clinical trials are also being conducted in US, Japan, Russia, South Africa, Kenya, Latin America Planned trials in other European and Asian countries N = 60,000 Manufacturing capacity 3 billion doses in 2021 Storage / transport 2-8 degrees Celsius 36-46 degrees Fahrenheit For at least six months Administered within existing healthcare settings COV002 A single-blinded, multi-centre, randomised, controlled Phase II/III trial Assessing the safety, efficacy and immunogenicity of AZD1222 in 12,390 participants in the UK Aged 18 years or over Healthy or have medically stable chronic diseases and are at increased risk for being exposed to the SARS-CoV-2 virus Group one One or two intramuscular doses of a half dose (~2.5 x1010 viral particles) Comparator, meningococcal vaccine MenACWY. Group two Full dose (~5x1010 viral particles) Comparator, meningococcal vaccine MenACWY. Clinical assessments for safety as well as immunogenicity Multiple timepoints For a year Weekly swabbing for viral presence COV003 COV003 is a single-blinded, multi-centre, randomised, controlled Phase III trial in Brazil Two intramuscular doses of a full dose (~5x1010 viral particles) of AZD1222 or comparator Meningococcal vaccine MenACWY as first dose and a saline placebo as second dose UK, Oxford / Astrazeneca The UK has ordered 100m doses US also UK government has supplied £65.5m towards the development Contracts with France, Germany, Italy and the Netherlands, up to 400 million doses Serum Institute of India, vaccine alliances, production for poorer countries, 1 billion doses China, Brazil, Japan and Russia have also expressed interest.